Skip to content
Sign in

VNDA · NASDAQ

Vanda Pharmaceuticals (VNDA) Stock Price & Fundamentals

$426.32+1.14%+$4.80End-of-day price as of Oct 9, 2026

Vanda Pharmaceuticals (VNDA) closed at $426.32 on Oct 9, 2026, up 1.14% from the previous close of $421.52.

Share price, past year

1Y +37.91%

52-week range $304.61 – $445.87. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$426.32
Sep 30, 2026$424.37
Aug 31, 2026$436.14
Jul 31, 2026$431.20
Jun 30, 2026$424.16
May 29, 2026$406.00
Apr 30, 2026$394.34
Mar 31, 2026$398.77
Feb 27, 2026$384.00
Jan 30, 2026$349.79
Dec 31, 2025$323.69
Nov 28, 2025$319.26
Oct 31, 2025$319.18

Key statistics

Market cap
$25.77B
P/E (TTM)
—
EPS (TTM)
−$4.64
Revenue (TTM)
$215.72M
Net income (TTM)
−$274.85M
Shares outstanding
60.5M
Dividend yield
—
52-week range
$304.61 – $445.87

Vanda Pharmaceuticals's market cap is $25.77B, based on a share price of $426.32 and 60.5M shares outstanding as of Jun 30, 2026.

Financials

Vanda Pharmaceuticals reported revenue of $216.11M for fiscal 2025, up 8.72% from fiscal 2024.

Vanda Pharmaceuticals reported a net loss of $220.47M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Vanda Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$216.11M+8.7%−$220.47M−102.0%−$3.74−$110.44M
FY2024ended Dec 31, 2024$198.77M+3.2%−$18.90M−9.5%−$0.33−$16.25M
FY2023ended Dec 31, 2023$192.64M−24.3%$2.51M1.3%$0.04$12.42M
FY2022ended Dec 31, 2022$254.38M−5.3%$6.28M2.5%$0.11$31.31M
FY2021ended Dec 31, 2021$268.68M+8.3%$33.15M12.3%$0.58$63.66M
FY2020ended Dec 31, 2020$248.17M+9.2%$23.34M9.4%$0.42$49.98M
FY2019ended Dec 31, 2019$227.19M+17.6%$115.55M50.9%$2.11$44.93M
FY2018ended Dec 31, 2018$193.12M+17.0%$25.21M13.1%$0.48$29.62M
FY2017ended Dec 31, 2017$165.08M+13.1%−$15.57M−9.4%−$0.35−$3.65M
FY2016ended Dec 31, 2016$146.02M—−$18.01M−12.3%−$0.41—
Vanda Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$50.53M−$62.51M−$1.04
Q1 FY2026ended Mar 31, 2026$51.72M−$48.57M−$0.82
Q4 FY2025ended Dec 31, 2025$57.22M−$141.19M−$2.40
Q3 FY2025ended Sep 30, 2025$56.26M−$22.59M−$0.38
Q2 FY2025ended Jun 30, 2025$52.59M−$27.21M−$0.46
Q1 FY2025ended Mar 31, 2025$50.04M−$29.49M−$0.50
Q4 FY2024ended Dec 31, 2024$53.19M−$4.91M−$0.09
Q3 FY2024ended Sep 30, 2024$47.65M−$5.32M−$0.09

Company profile

Name
Vanda Pharmaceuticals Inc.
Ticker
VNDA
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
2200 Pennsylvania Ave Nw, Suite 300e, Washington, DC 20037
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001347178

Recent SEC filings

Frequently asked questions

What is Vanda Pharmaceuticals's stock price?

Vanda Pharmaceuticals (VNDA) closed at $426.32 on Oct 9, 2026, up 1.14% from the previous close of $421.52.

What is Vanda Pharmaceuticals's market cap?

Vanda Pharmaceuticals's market cap is $25.77B, based on a share price of $426.32 and 60.5M shares outstanding as of Jun 30, 2026.

How much revenue does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals reported revenue of $216.11M for fiscal 2025, up 8.72% from fiscal 2024.

Does Vanda Pharmaceuticals pay a dividend?

Vanda Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Vanda Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures